Ambry delivers high-quality, accessible genetic testing for hereditary cancer and exome sequencing for rare disease. A trusted lab for 25 years.

Discover why Ambry Genetics can help you provide more accurate results for your patients. Learn more today.

Ambry is committed to delivering the most accurate genetic test results possible. Learn more today.

Feb 3, 2025 · Ambry Genetics will continue operations as a wholly-owned subsidiary of Tempus under its current leadership team. About Tempus Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating ...

Feb 3, 2025 · CHICAGO--(BUSINESS WIRE)--Feb. 3, 2025-- Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its acquisition of Ambry Genetics, a recognized leader in genetic testing that aims to improve health by understanding the relationship between ...

Feb 3, 2025 · Tempus Completes Acquisition of Ambry Genetics. Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it ...

Nov 11, 2024 · Tempus AI has announced its acquisition of Ambry Genetics, from KONICA MINOLTA, INC. for $600 million, comprising $375 million in cash and $225 million in shares. This strategic acquisition expands Tempus’ capabilities in hereditary cancer screening and genetic testing, adding to its precision medicine offerings.

Feb 3, 2025 · CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced it has completed its ...

Feb 4, 2025 · Ambry Genetics will continue operations as a wholly-owned subsidiary of Tempus under its current leadership team. About Tempus. Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating ...

Nov 6, 2024 · Tempus AI agreed to buy genetic testing company Ambry Genetics for $375 million in cash and $225 million in shares. Chicago-based Tempus, which makes AI-enabled precision medicine solutions, said the purchase will provide expanded testing …